Elscint's U.S. sales take bigger share

Article

Elscint has shown progressin increasing its position in the U.S. market. Historically, theIsraeli-based medical imaging vendor has been stronger in Europethan in the U.S. With scanner sales sagging in both markets, Elscintviews boosting its U.S. share as

Elscint has shown progressin increasing its position in the U.S. market. Historically, theIsraeli-based medical imaging vendor has been stronger in Europethan in the U.S. With scanner sales sagging in both markets, Elscintviews boosting its U.S. share as an opportunity to maintain itsrevenues.

The vendor saw revenue rise 8% in fiscal 1993 (end-December)to $238 million from $221 million in 1992. However, U.S. saleswere up nearly 50% for the year. Net income rose 7% -- not countingthe $4.8 million positive effect of a change in accounting methods-- from $20 million in 1992 to $21.5 million last year.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.